Research progress on the forkhead box C1

Jinhua Wang _, Wan Li, Xiangjin Zheng, Xiaocong Pang and Guanhua Du

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:12471-12478. https://doi.org/10.18632/oncotarget.22527

Metrics: PDF 2222 views  |   HTML 3107 views  |   ?  


Jinhua Wang1,2, Wan Li2, Xiangjin Zheng2, Xiaocong Pang2 and Guanhua Du1,2

1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China

2Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China

Correspondence to:

Jinhua Wang, email: [email protected]

Guanhua Du, email: [email protected]

Keywords: FOX family; FOXC1; cancer; drug resistance; stem cell

Received: July 29, 2017     Accepted: November 01, 2017     Published: November 20, 2017


FOXC1 is a vital member of FOX families which play important roles in biological processes including proliferation, differentiation, apoptosis, migration, invasion, metabolism, and longevity. Here we are focusing on roles of FOXC1 and their mechanisms in cancers. FOXC1 promoted progress of many cancers, such as breast cancer (especially basal-like breast cancer), hepatocellular carcinoma, gastric cancer and so on. FOXC1 was also found to be associated with drug resistance of cancers. FOXC1 promoted metastasis of cancers by increasing expression of MMP7, NEDD9 and Snail. Proliferation and invasion of cancers were increased by FOXC1 by mediating NF-κB, MST1R and KLF4 expression. FOXC1 was associated with development by regulating expression of FGF19 and MSX1. Recently, FOXC1 was found to be required for niche of stem cells or development of stem cells by mediating expression of Gli2, CXCL12, SCF, NFATC1, BMP and Myh7. Overall, FOXC1 exerts its functions by many mechanisms and may be used as a potential biomarker for diseases.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22527